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1 |  INTRODUCTION
We report a new phenotype of chorea combining choreic 
movements and an early freezing of gait (FOG). Genetic 
screening for the following gene mutations was negative: 
HTT (HD), JPH3 (HDL2), TBP (SCA17), ATN1 (DRPLA), 
and C9ORF72. The early FOG episodes could be due to de-
generation of the direct striato-pallidal pathway.
Huntington's disease (HD) is an autosomal dominant dis-
ease caused by a mutation of the IT15 gene which is located 
on chromosome 4 and is responsible for an expanded trinu-
cleotide cytosine-adenosine-guanosine repeat sequence.1 
During the course of chorea, a progressive akinetic-rigid-dys-
tonic syndrome appears at the more advanced stages of the 
disease and masks the choreic movements, which abate dra-
matically. After obtaining the informed written consent, we 
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Abstract
The early onset of gait akinesia should not rule out the diagnosis of hereditary chorea. 
It would be helpful to proceed to a whole-genome and long-read sequencing in order 
to track a new pathogenic variant including noncoding repeat expansion.
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report a case of an idiopathic choreic syndrome combining 
chorea associated with early severe freezing of gait (FOG).
2 |  CASE PRESENTATION
A 66-year-old man had experienced choreic movements and 
falls due to FOG for 6 years. The syndrome was character-
ized by choreic movements of the face, trunk, and four limbs 
(see Video S1, segment 1) leading to a score of 20/124 on the 
motor part of the Unified Huntington's Disease Rating Scale 
(UHDRS).2 Gait was dramatically impaired by severe festi-
nation and FOG responsible for imbalance and falls 1 year 
after disease onset (see Video S1, segment 2). No segmental 
akinesia or rigidity was observed in any of the four limbs. 
Oculomotricity was impaired with interrupted vertical pur-
suit, as well as swallowing and speech. Cognitive functions 
were impaired on the mnemonic slope, but verbal fluency and 
visuo-constructive functions were preserved. Cerebrospinal 
fluid was not analyzed, and brain (T1, T2 FLAIR, DWI, T2*) 
and medullary magnetic resonance imaging showed discrete 
atrophy of the caudate nucleus, cerebellum, and spinal cord. 
An autosomal dominant transmission was suspected because 
his deceased mother had exhibited abnormal movements 
from the age of 61 years. However, his father, two brothers, 
three sisters, and three children were symptom-free. No in-
formation on his maternal grandparents was available.
Genetic screening for the following gene mutations was neg-
ative: HTT (HD) (17-22 CAG), JPH3 (HDL2), TBP (SCA17), 
ATN1 (DRPLA), VPS13A, and C9ORF72. In addition, routine 
pan-genomic array comparative genomic hybridization (CGH; 
Human660-Quad v1.0 DNA Analysis BeadChip; Illumina) re-
vealed no gene dosage abnormalities. A dopamine transporter 
scan (DAT scan) showed values at the lower limit in the stria-
tum (index for the left and right striatum = 2.19; normal 2.22-
4.17). Electromyographic surface electrodes were used in order 
F I G U R E  1  Muscular activation 
patterns observed during normal gait and 
freezing of gait. A, Surface electrodes were 
used to record muscular activity of the 
left and right (not shown) gastrocnemius, 
anterior tibialis, biceps femoris, and vastus 
lateralis during period of gait without 
freezing. B, Repetitive muscular activity 
recorded during freezing of gait (FOG). 
A cocontraction index (CCI) revealed 
an increase in antagonist muscular 
cocontractions, especially in the left 
proximal muscles during the FOG episodes 
(CCI = 322.0 during gait without FOG vs 
2880.1 during FOG; (A,B)). Cocontraction 
index: CCI = (EMG1 + EMG2) × min 
[EMG1 EMG2]/max [EMG1 EMG2]
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to characterize his gait (Figure 1A,B). During the FOG episodes 
(see Video S1, segment 2), a disorganized muscular activity of 
the left biceps femoris, vastus lateralis, gastrocnemius, and an-
terior tibialis was observed (Figure 1B).
Levodopa therapy was not tested because no significant 
dopaminergic degeneration was observed on the DAT scan 
results and because chorea was disabling, so that we did not 
take the risk of increasing involuntary movements by intro-
ducing dopamine replenish therapy. On the other hand, a 
treatment with tetrabenazine was initiated at a daily dosage 
of 12.5 mg and progressively increased up to the dosage of 
62.5  mg/d. Despite we observed a significant decrease of 
chorea with this dosage, FOG and swallowing dramatically 
impaired and necessitated to stop the therapy.
3 |  DISCUSSION
Although the molecular diagnosis is not yet available, the 
phenotype of this choreic syndrome is of particular interest 
because this patient exhibited concomitant dramatic hyper-
kinetic and hypokinetic symptoms without significant dopa-
minergic denervation, as attested by the DAT scan results. 
Such early dramatic akinesia of the lower limbs associated 
with choreic movements has not been reported previously in 
choreic syndromes. During the first years of the disease, the 
medium spiny neurons constitutive of the indirect striato-pal-
lidal pathway degenerate preferentially, thereby explaining 
the hyperkinetic syndrome.1 On the other hand, the hypoki-
netic characteristics of gait usually appear as the disease 
progresses, with degeneration affecting the direct striato-
pallidal pathway and the substantia nigra pars compacta.3-6 
At this later stage, the choreic syndrome tends to abate. In 
our patient, the FOG episodes could reflect a severe akinesia 
restricted to the lower limbs that cannot be explained by do-
paminergic degeneration but is more likely due to early de-
generation of the direct striato-pallidal pathway. Moreover, 
neither comorbidities nor neuroleptic exposure could explain 
such gait disturbances.
4 |  CONCLUSION
In summary, this case reveals a new phenotype of chorea 
combining choreic movements and severe gait akinesia. Its 
molecular basis remains to be identified as it does not fit any 
of the gene profiles for the more frequent choreic syndromes. 
Whole-genome sequencing and long-read sequencing to look 
for noncoding repeat expansion would be highly valuable in 
familiar neurodegenerative disorders including the clinical 
situation described here. 7
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